|
SECURITIES AND EXCHANGE COMMISSION
|
|
Washington, D.C. 20549
|
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
(Amendment No. 1)*
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND
(d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
DARIOHEALTH CORP.
|
||
|
(Name of Issuer)
|
||
|
Common Stock, par value $0.0001 per share
|
||
|
(Title of Class of Securities)
|
||
|
23725P209
|
||
|
(CUSIP Number)
|
||
|
December
31, 2022
|
||
|
(Date of Event Which Requires Filing of this Statement)
|
||
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP NO. 86745K104
|
1
|
Name of Reporting Persons/
I.R.S. Identification Nos. of above persons (entities only). |
|
|
||
|
Clal Insurance Enterprises Holdings Ltd.
|
|
|
|||
|
|
|
||||
|
2
|
Check the Appropriate Box if a Member of a Group
|
||||
|
(a)☐
|
|||||
|
(b)☐
|
|
|
|||
|
3
|
SEC Use only
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
Place of Organization
|
|
|
||
|
Israel
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
Sole Voting Power
|
|
|
|
|
0
|
|
|
|||
|
|
|
||||
|
6
|
Shared Voting Power
|
|
|
||
|
1,066,561 Shares *
|
|
|
|||
|
|
|
||||
|
7
|
Sole Dispositive Power
|
|
|
||
|
0
|
|
|
|||
|
|
|
||||
|
8
|
Shared Dispositive Power
|
|
|
||
|
1,066,561 Shares *
|
|
|
|||
|
|
|
||||
|
9
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
|
|
||
|
1,066,561 Shares *
|
|
|
|||
|
|
|
||||
|
10
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
|
|
|
||
|
☐
|
|
|
|||
|
|
|
||||
|
11
|
Percent of Class Represented by Amount in Row (9)
|
|
|
||
|
4.2%**
|
|
|
|||
|
|
|
||||
|
12
|
Type of Reporting Person :
|
|
|
||
| CO |
|
|
|||
|
|
|
||||
* See Item 4.
** Based on 25,679,410 shares of Common Stock
of the Issuer outstanding as of December 28, 2022 (as reported by the Issuer in its report on Form S-3 filed with the Securities and Exchange Commission on December 30, 2022.
Item 1.
| (a) |
Name of Issuer:
DARIOHEALTH CORP. (the “Issuer”). |
| (b) |
Address of Issuer’s Principal Executive Offices:
18 W. 18th St, 5th Floor, New York, New York 10011.
|
Item 2.
| (a) |
Name of Person Filing:
|
Clal Insurance Enterprises Holdings Ltd. (“Clal” or the “Reporting Person”). Clal, an Israeli public corporation, may be deemed to beneficially own the Shares (as defined below) reported in this Statement. See Item 4.
| (b) |
Address of Principal Business Offices or, if none, Residence:
|
Clal Insurance Enterprises Holdings Ltd. – 36 Raul Walenberg St., Tel Aviv 66180, Israel.
| (c) |
Place of Organization:
|
Israel.
(d) Title of Class of Securities:
Common Stock, par value $0.0001 per share (the “Shares”).
| (e) |
CUSIP Number:
|
23725P209
| Item 3. |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable. |
| Item 4. |
Ownership
|
Of the 1,066,561 Shares reported in this Statement as beneficially owned by Clal, (i) 23 Shares are beneficially held for its own account; and (ii) 1,066,538 Shares are held for members of the public through, among others, provident funds
and/or pension funds and/or insurance policies, which are managed by subsidiaries of Clal, which subsidiaries operate under independent management and make independent voting and investment decisions. Consequently, this Statement shall not be
construed as an admission by Clal, that it is the beneficial owner of more than 23 Shares covered by this Statement.
Except as set forth above, see items 5-11 of the cover page hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which are
incorporated herein.
| Item 5. |
Ownership of 5 Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒. |
| Item 6. |
Ownership of More than 5 Percent on Behalf of Another Person
Not applicable. |
| Item 7. |
Identification and Classification of the Subsidiary, Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
Not applicable. |
| Item 8. |
Identification and Classification of Members of the Group
Not applicable. |
Item 9. Notice of Dissolution of Group
Not applicable.
Not applicable.
Item 10. Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
February 12, 2023
|
|
|
CLAL INSURANCE ENTERPRISES HOLDINGS LTD.
BY: /s/ Eran Czerninski /s/ Tomer David
Eran Czerninski and Tomer
David, authorized signatories of CLAL INSURANCE ENTERPRISES HOLDINGS LTD.
|